The Clinical Potential of Antiangiogenic Fragments of Extracellular Matrix Proteins
Author Information
Author(s): Clamp A R, Jayson G C
Primary Institution: Cancer Research UK Department of Medical Oncology, Christie Hospital
Hypothesis
Can antiangiogenic fragments of extracellular matrix proteins be effective in cancer treatment?
Conclusion
The study highlights the potential of antiangiogenic fragments but notes that clinical trials, particularly with endostatin, have not shown significant antitumor activity.
Supporting Evidence
- Endostatin showed consistent pharmacokinetics but no formal disease responses were observed in trials.
- Some patients experienced minor responses, but these were not dose-related.
- Phase I trials indicated safety but lacked significant antiangiogenic activity.
Takeaway
Some proteins in our body can help stop cancer from growing by blocking blood vessel formation, but tests on one of these proteins, endostatin, didn't work as well as hoped.
Methodology
The review discusses various studies and trials involving antiangiogenic fragments, particularly focusing on endostatin and its clinical trials.
Potential Biases
Potential immunogenicity and the influence of pre-existing elevated endostatin levels in cancer patients may bias results.
Limitations
The trials faced issues with trial design, patient selection, and the lack of a clearly defined mechanism of action for endostatin.
Participant Demographics
Patients with advanced metastatic cancer, including various types such as melanoma, sarcoma, and colorectal cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website